Peter S. Kim Buys 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Free Report) Director Peter S. Kim bought 1,512 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were purchased at an average price of $13.75 per share, for a total transaction of $20,790.00. Following the purchase, the director now owns 60,336 shares in the company, valued at approximately $829,620. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $13.88 on Wednesday. The firm’s 50 day moving average price is $13.74 and its 200-day moving average price is $14.51. Entrada Therapeutics, Inc. has a 1 year low of $10.62 and a 1 year high of $18.44. The stock has a market cap of $466.37 million, a P/E ratio of -53.38 and a beta of -0.50.

Entrada Therapeutics (NASDAQ:TRDAGet Free Report) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.22). Entrada Therapeutics had a negative return on equity of 2.89% and a negative net margin of 5.18%. The business had revenue of $41.85 million during the quarter, compared to the consensus estimate of $27.82 million. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post -1.54 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on TRDA shares. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research note on Monday, March 18th. Oppenheimer started coverage on shares of Entrada Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $22.00 target price on the stock.

View Our Latest Report on TRDA

Institutional Investors Weigh In On Entrada Therapeutics

Several large investors have recently bought and sold shares of TRDA. TD Asset Management Inc boosted its stake in Entrada Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 119,254 shares of the company’s stock worth $1,884,000 after buying an additional 59,627 shares during the period. Wellington Management Group LLP boosted its stake in Entrada Therapeutics by 2.6% during the third quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company’s stock worth $16,521,000 after buying an additional 26,144 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in Entrada Therapeutics during the third quarter worth $44,000. SG Americas Securities LLC purchased a new position in Entrada Therapeutics during the third quarter worth $145,000. Finally, Cubist Systematic Strategies LLC boosted its stake in Entrada Therapeutics by 927.2% during the first quarter. Cubist Systematic Strategies LLC now owns 4,160 shares of the company’s stock worth $60,000 after buying an additional 3,755 shares during the period. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

Featured Articles

Insider Buying and Selling by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.